Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Conjunctivitis is a known comorbidity of atopic dermatitis. Dupilumab clinical trials for moderate-to-severe atopic dermatitis in adults showed a higher conjunctivitis incidence for dupilumab-treated patients than placebo-treated patients, whereas trials for uncontrolled asthma reported lower rates for both dupilumab and placebo. OBJECTIVE: The objective of this study was to evaluate the incidence and severity of conjunctivitis in dupilumab clinical trials in adolescents with moderate-to-severe atopic dermatitis or uncontrolled asthma. METHODS: We evaluated the incidence of conjunctivitis in adolescents (aged 12 to < 18 years) in three phase III trials. Ocular events were diagnosed and treated based on patient-reported symptoms and an external eye examination by study investigators, in most cases without an ophthalmologic referral. In LIBERTY AD ADOL (16-week, randomized, placebo-controlled, double-blinded trial), adolescents with moderate-to-severe atopic dermatitis were randomized to subcutaneous placebo, dupilumab 300 mg every 4 weeks, or dupilumab every 2 weeks (200 mg, patients < 60 kg at baseline; 300 mg, ≥ 60 kg at baseline). In LIBERTY AD PED-OLE (open-label extension), pediatric patients from previous dupilumab atopic dermatitis trials received dupilumab 2 mg/kg or 4 mg/kg weekly (up to 300 mg) or 300 mg every 4 weeks. In LIBERTY ASTHMA QUEST (randomized, double-blinded, placebo-controlled trial), patients with uncontrolled moderate-to-severe asthma were randomized to 52 weeks of add-on therapy with dupilumab 200 or 300 mg every 2 weeks or matched-volume placebo. RESULTS: In ADOL, more dupilumab-treated (17/165; 10.3%) than placebo-treated patients (4/85; 4.7%) reported one or more conjunctivitis event. All events were mild to moderate in severity; 12 (7.3%) dupilumab-treated and 4 (4.7%) placebo-treated patients received treatment. Most patients with conjunctivitis (dupilumab, 12/17; placebo, 4/4) recovered/resolved during the treatment period. The risk of conjunctivitis showed no relationship with dupilumab serum concentration. In PED-OLE, 12/275 adolescents (4.4%) reported one or more conjunctivitis event. Most conjunctivitis events were mild to moderate. Ten patients received treatment for conjunctivitis. Ten patients recovered/resolved during the study. In QUEST, similar low proportions of dupilumab-treated (2/68, 2.9%) and placebo-treated (1/39, 2.6%) adolescents reported one or more conjunctivitis event. All events were mild to moderate. One dupilumab-treated patient received treatment for conjunctivitis. All cases recovered/resolved during the study. No patients in these trials discontinued study treatment temporarily or permanently because of conjunctivitis. In ADOL, one case of unspecified viral keratitis (specific viral etiology not known) in the dupilumab 300-mg every 4 weeks group and one case of allergic blepharitis in the placebo group were reported; both events resolved during the treatment period, and neither led to treatment discontinuation. CONCLUSIONS: Dupilumab-treated adolescents in atopic dermatitis trials had a higher incidence of conjunctivitis than placebo-treated patients, whereas overall rates of conjunctivitis among adolescents in the asthma trial were lower than in atopic dermatitis trials and were similar for dupilumab- and placebo-treated patients. Most events were mild to moderate, most recovered/resolved, and none prompted study withdrawal. These results are similar to those reported in adult trials and support a drug-disease interaction. CLINICALTRIALS. GOV IDENTIFIERS: NCT03054428, NCT02612454, NCT02414854. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma (MP4 18453 kb).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Time to first conjunctivitis event, and exposure–response relationship. a Time to first conjunctivitis event in ADOL. b Relationship between exposure and risk of developing conjunctivitis in ADOL: logistic regression relating probability of developing conjunctivitis with dupilumab trough concentration at week 16. The mean regression line is blue, and the confidence interval around the regression line is represented by the gray area. Patients without any conjunctivitis events are shown at the bottom of the figure and those with one or more conjunctivitis event are shown at the top of the figure; the open green circles (300 mg q4w) and open red squares (200/300 mg q2w) are offset so that each circle/square can be seen. The y-axis represents the probability of a patient reporting one or more conjunctivitis event. Means of response variables (open black circles) and confidence intervals (green vertical lines) around the means are presented in the figures by quartile of exposure. c Time to first conjunctivitis event in PED-OLE. Time to onset of first conjunctivitis event was based on the compiled overall conjunctivitis definition that included all component MedDRA PTs [conjunctivitis, conjunctivitis allergic, conjunctivitis bacterial, conjunctivitis viral, conjunctivitis adenoviral, and atopic keratoconjunctivitis]. “Censored” (i.e., vertical crossbars) refers to patients in the overall population who discontinued from the study. MedDRA Medical Dictionary for Regulatory Activities, PT MedDRA Preferred Term, qw once weekly, q2w every 2 weeks, q4w every 4 weeks](https://figures.cochat.ai/paper-figures/3729a1f6beb5416b85dfd4144abda6cd/conjunctivitis-in-dupilumab-clinical-trials-for-adolescents-with-atopic-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Higher rates were described in long-term studies and in real-world reports83–86 but interestingly not in asthma94.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationDupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986 · cited 4×
“LIBERTY ASTHMA QUEST (QUEST; EFC13579, ClinicalTrials.gov Identifier: NCT02414854) [23] was a randomized, double-blinded, placebo-controlled, parallelgroup, phase III trial.”
MethodSelf-citationDupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184
Self-citationWenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationBachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
Self-citationThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572 · cited 1×
“In adults in randomized, placebo-controlled doubleblinded clinical trials for moderate-to-severe AD, a higher incidence of conjunctivitis was observed in patients who received dupilumab compared with those who received placebo [16, 17, 20, 21, 26].”
BackgroundSelf-citationLe Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., Bai, Y., Lim, W. K., Martin, J., Huang, T., et al. (2020) · Allergy · doi:10.1111/all.14151 · Cited by 545
Simpson, E. L., Paller, A. S., Siegfried, E. C., Boguniewicz, M., Sher, L., Gooderham, M. J., Beck, L. A., Guttman-Yassky, E., Pariser, D., Blauvelt, A., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3336 · Cited by 524 · cited 5×
“In adults in randomized, placebo-controlled doubleblinded clinical trials for moderate-to-severe AD, a higher incidence of conjunctivitis was observed in patients who received dupilumab compared with those who received placebo [16, 17, 20, 21, 26].”
BackgroundMethodSelf-citationde Bruin-Weller, M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479 · cited 1×
“In adults in randomized, placebo-controlled doubleblinded clinical trials for moderate-to-severe AD, a higher incidence of conjunctivitis was observed in patients who received dupilumab compared with those who received placebo [16, 17, 20, 21, 26].”
BackgroundSelf-citationHamilton, J. D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 469
Self-citationEfficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
Hirano, I., Dellon, E. S., Hamilton, J. D., Collins, M. H., Peterson, K., Chehade, M., Schoepfer, A. M., Safroneeva, E., Rothenberg, M. E., Falk, G. W., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.042 · Cited by 460
Self-citationMurphy, A. J., Macdonald, L. E., Stevens, S., Karow, M., Dore, A. T., Pobursky, K., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 455 · cited 1×
“Dupilumab is a fully human, VelocImmune®-derived [11, 12] monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, which are key and central drivers of type 2 inflammation.”
BackgroundConjunctivitis in dupilumab clinical trials
Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17869 · Cited by 442 · cited 10×
“By contrast, there was a trend in adults for a decreased incidence of conjunctivitis with increased exposure to dupilumab [26].”
BackgroundMethodResultSelf-citationPrecise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
Macdonald, L. E., Karow, M., Stevens, S., Auerbach, W., Poueymirou, W. T., Yasenchak, J., Frendewey, D., Valenzuela, D. M., Giallourakis, C. C., Alt, F. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323896111 · Cited by 391 · cited 1×
“Dupilumab is a fully human, VelocImmune®-derived [11, 12] monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, which are key and central drivers of type 2 inflammation.”
BackgroundDeleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.074 · Cited by 255
Self-citationTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1700366 · Cited by 219
Self-citationWorm, M., Simpson, E. L., Thaçi, D., Bissonnette, R., Lacour, J.-P., Beissert, S., Kawashima, M., Ferrándiz, C., Smith, C. H., Beck, L. A., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3617 · Cited by 214
Self-citationWollenberg, A., Ariens, L., Thurau, S., van Luijk, C., Seegräber, M., & de Bruin-Weller, M. (2018) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.01.034 · Cited by 180
Epidemiology of allergic conjunctivitis
Rosario, N., & Bielory, L. (2011) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e32834a9676 · Cited by 177
Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis
Thyssen, J. P., Toft, P. B., Halling, A., Gislason, G., Skov, L., & Egeberg, A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.03.003 · Cited by 170 · cited 1×
“Prevalence of these ocular surface comorbidities increases with AD severity [3].”
BackgroundOcular complications of atopic dermatitis.
Garrity, J. A., & Liesegang, T. J. (1984) · PubMed · Cited by 164
Simpson, E. L., Gadkari, A., Worm, M., Soong, W., Blauvelt, A., Eckert, L., Wu, R., Ardeleanu, M., Graham, N. M. H., Pirozzi, G., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.04.054 · Cited by 160
Self-citationBakker, D. S., Ariens, L. F. M., Luijk, C., Schaft, J., Thijs, J. L., Schuttelaar, M. L. A., Wijk, F., Knol, E. F., Balak, D. M. W., Dijk, M. R., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17538 · Cited by 157
Atopic keratoconjunctivitis: A review
Chen, J. J., Applebaum, D. S., Sun, G. Y., & Pflugfelder, S. C. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.036 · Cited by 156
Cork, M. J., Thaçi, D., Eichenfield, L. F., Arkwright, P. D., Hultsch, T., Davis, J. D., Zhang, Y., Zhu, X., Chen, Z., Li, M., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18476 · Cited by 154 · cited 4×
“LIBERTY AD PED-OLE (PED-OLE; R668-AD-1434, ClinicalTrials.gov Identifier: NCT02612454) [19] was a phase III OLE available to pediatric patients who participated in a previous dupilumab AD trial.”
BackgroundMethodSelf-citationRisk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis
Treister, A. D., Kraff-Cooper, C., & Lio, P. A. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.2690 · Cited by 135
Atopic Dermatitis and Keratoconjunctivitis
Bielory, B. P., & Bielory, L. (2010) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2010.06.004 · Cited by 109
Drug Evaluation Review: Dupilumab in Atopic Dermatitis
Hamilton, J. D., Ungar, B., & Guttman-Yassky, E. (2015) · Immunotherapy · doi:10.2217/imt.15.69 · Cited by 93
Self-citationPaller, A. S., Bansal, A., Simpson, E. L., Boguniewicz, M., Blauvelt, A., Siegfried, E. C., Guttman‐Yassky, E., Hultsch, T., Chen, Z., Mina‐Osorio, P., et al. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00478-y · Cited by 84
Self-citationOcular Complications of Atopic Dermatitis and Other Eczemas
Rich, L. F., & Hanifin, J. M. (1985) · International Ophthalmology Clinics · doi:10.1097/00004397-198502510-00005 · Cited by 80
Higher mortality of adults with asthma: A 15‐year follow‐up of a population‐based cohort
Lemmetyinen, R. E., Karjalainen, J. V., But, A., Renkonen, R. L. O., Pekkanen, J. R., Toppila‐Salmi, S. K., & Haukka, J. K. (2018) · Allergy · doi:10.1111/all.13431 · Cited by 70
RItA: The Italian severe/uncontrolled asthma registry
Maio, S., Baldacci, S., Bresciani, M., Simoni, M., Latorre, M., Murgia, N., Spinozzi, F., Braschi, M., Antonicelli, L., Brunetto, B., et al. (2017) · Allergy · doi:10.1111/all.13342 · Cited by 66
Thyssen, J. P. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16330 · Cited by 66
A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis
Agnihotri, G., Shi, K., & Lio, P. (2019) · Drugs in R&D · doi:10.1007/s40268-019-00288-x · Cited by 66
Prevalence and comorbidity of allergic diseases in preschool children
Kim, H. Y., Kwon, E. B., Baek, J. H., Shin, Y. H., Yum, H. Y., Jee, H. M., Yoon, J. W., & Han, M. Y. (2013) · Korean Journal of Pediatrics · doi:10.3345/kjp.2013.56.8.338 · Cited by 61
Touhouche, A. T., Cassagne, M., Bérard, E., Giordano‐Labadie, F., Didier, A. P., Fournié, P., Paul, C. F., & Tauber, M. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16724 · Cited by 60 · cited 1×
“In addition, some prescribers have used prophylactic tears on starting dupilumab therapy, to address potential issues of eye dryness [55, 56].”
BackgroundAtopic dermatitis is associated with increased prevalence of multiple ocular comorbidities
Govind, K., Whang, K. A., Khanna, R., Scott, A. W., & Kwatra, S. G. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.10.009 · Cited by 59
Systemic and local immunological features of atopic dermatitis patients with ocular complications
Uchio, E., Miyakawa, K., Ikezawa, Z., & Ohno, S. (1998) · British Journal of Ophthalmology · doi:10.1136/bjo.82.1.82 · Cited by 48
Dupilumab-Induced Follicular Conjunctivitis
Shen, E., Xie, K., Jwo, K., Smith, J. E., & Mosaed, S. (2018) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2018.1533567 · Cited by 44
Ocular complications of atopic dermatitis.
Hsu, J. I., Pflugfelder, S. C., & Kim, S. J. (2019) · PubMed · Cited by 42
Wu, M., Wang, X., Han, J., Shao, T., & Wang, Y. (2019) · BMC Ophthalmology · doi:10.1186/s12886-019-1074-5 · Cited by 41
Management of dupilumab‐associated conjunctivitis in atopic dermatitis
Aszodi, N., Thurau, S., Seegräber, M., de Bruin‐Weller, M., & Wollenberg, A. (2019) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13809 · Cited by 40
Ulcerative blepharitis in atopic patients--is Candida species the causative agent?
Huber‐Spitzy, V., Böhler‐Sommeregger, K., Arocker‐Mettinger, E., & Grabner, G. (1992) · British Journal of Ophthalmology · doi:10.1136/bjo.76.5.272 · Cited by 33
Uchida, H., Kamata, M., Nagata, M., Fukaya, S., Hayashi, K., Fukuyasu, A., Tanaka, T. L., Ishikawa, T., Ohnishi, T., & Tada, Y. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.039 · Cited by 33 · cited 1×
“Retrospective studies of dupilumab-treated patients with AD in clinical practice also showed significant positive associations of certain biomarkers (TARC, IgE) and prior history of ocular disorders, with an increased risk of conjunctivitis [41, 42].”
BackgroundRaffi, J., Suresh, R., Fishman, H. A., Botto, N. C., & Murase, J. E. (2019) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2019.10.001 · Cited by 24 · cited 1×
“Retrospective studies of dupilumab-treated patients with AD in clinical practice also showed significant positive associations of certain biomarkers (TARC, IgE) and prior history of ocular disorders, with an increased risk of conjunctivitis [41, 42].”
BackgroundATOPIC DERMATITIS: OCULAR CHANGES
Sehgal, V. N., & Jain, S. (1994) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1994.tb01484.x · Cited by 20
Michailopoulos, P., Almaliotis, D. D., Irini, G., Papakosta, D., Gougoulias, K., Giouleka, P., Gioulekas, D. G., Siempis, T., & Karampatakis, V. E. (2017) · Medical Hypothesis Discovery & Innovation in Ophthalmology · Cited by 19
Braude, L. S., & Chandler, J. (1984) · PubMed · Cited by 18
Rial, M. J., Barroso, B., Rodríguez-Bermejo, C., & Sastre, J. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.10.055 · Cited by 17 · cited 1×
“In addition, some prescribers have used prophylactic tears on starting dupilumab therapy, to address potential issues of eye dryness [55, 56].”
Background[Eye complications in atopic dermatitis].
Ohmachi, N., Sasabe, T., Kojima, M., Adachi, J., Endo, K., Fukuzumi, T., & Aoki, T. (1994) · PubMed · Cited by 15
Management der Dupilumab‐assoziierten Konjunktivitis beim atopischen Ekzem
ASZODI, N., THURAU, S. R., Seegräber, M., de Bruin-Weller, M. S., & Wollenberg, A. (2019) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13809_g · Cited by 7
Rabe, K., Nair, P., Brusselle, G., Maspero, J., Castro, M., Zhu, H., Staudinger, H. W., Pirozzi, G., Antoni, C., Amin, N., et al. (2018) · Ghent University Academic Bibliography (Ghent University) · doi:10.1164/ajrccm-conference.2018.197.1_meetingabstracts.a7712 · Cited by 7
Self-citationNonsteroid management of residual ocular surface disease on dupilumab (ROSDD),
Raffi, J., Suresh, R., Berger, T. G., Fishman, H. A., & Murase, J. E. (2019) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2019.08.007 · Cited by 5
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Paller, A. S., Simpson, E. L., Siegfried, E. C., Cork, M. J., Wollenberg, A., Arkwright, P. D., Soong, W., Gonzalez, M. E., Schneider, L. C., Sidbury, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01539-2 · Cited by 281
Self-citationDupilumab-Associated Adverse Events During Treatment of Allergic Diseases
Kychygina, A., Cassagne, M., Tauber, M., Galiacy, S. D., Paul, C. F., Fournié, P., & Simon, M. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08934-0 · Cited by 103
Bangert, C., Alkon, N., Chennareddy, S., Arnoldner, T., Levine, J. P., Pilz, M., Medjimorec, M. A., Ruggiero, J. R., Cohenour, E. R., Jonak, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46540-0 · Cited by 86
From Emollients to Biologicals: Targeting Atopic Dermatitis
Salvati, L., Cosmi, L., & Annunziato, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910381 · Cited by 93
Metadata
- Authors
- Bansal, A., Simpson, E. L., Paller, A. S., Siegfried, E. C., Blauvelt, A., de Bruin-Weller, M., Corren, J., Sher, L., Guttman-Yassky, E., Chen, Z., Daizadeh, N., Kamal, M. A., Shumel, B., Mina-Osorio, P., Mannent, L., Patel, N., Graham, N. M. H., Khokhar, F. A., & Ardeleanu, M.
- Affiliations
- Regeneron (United States) (US)
- Oregon Health & Science University (US)
- Northwestern University (US)
- Cardinal Glennon Children’s Medical Center (US)
- Oregon Medical Research Center (US)
- University of California, Los Angeles (US)
- Sanofi (France) (FR)
- Sanofi (United States) (US)
- Corresponding author
- Bansal, Ashish
- ORCID
- Venue
- American Journal of Clinical Dermatology
- Published
- 2021-01
- Volume
- 22
- Issue
- 1
- Pages
- 101-115
- ISSN
- 1175-0561 (ISSN-L)
- 1179-1888
- PMC
- PMC7847457
- OpenAlex
- W3123842414
- Cited by
- 52
- References
- 57
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 9 · 2022: 14 · 2021: 8
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor, 21 d)
- Locations
- American Journal of Clinical Dermatology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Ophthalmology › Ocular Surface and Contact Lens
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- dupilumab, conjunctivitis, atopic dermatitis, uncontrolled asthma, adolescents, ocular adverse effects, drug safety, pediatric patients
- MeSH terms
- Adolescent, Adult, Age Factors, Asthma, Conjunctivitis, Dermatitis, Atopic, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Male, Placebos, Severity of Illness Index, Incidence, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase III as Topic, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.